TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.25 per share a year ago.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.23 per share a year ago.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Elizabeth Urish UP STRATEGIC WEALTH INVESTMENT ADVISORS LLC | 99,888 | $341,261.97 | $80,909.28 | -$260,352.69 | -76.29% |
James J. Karabas Embree Financial Group | 118,178 | $153,769.14 | $88,692.59 | -$65,076.55 | -42.32% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Antony Koblish CEO | NASDAQ (NMS) Exchange | 872381108 CUSIP |
| US Country | 218 Employees | - Last Dividend | - Last Split | 8 Nov 2019 IPO Date |
TELA Bio, Inc. is a commercial-stage medical technology company dedicated to innovating soft-tissue reconstruction solutions that aim to improve clinical outcomes while respecting the patient's anatomy. Established in 2012 and based in Malvern, Pennsylvania, the company targets improving surgical procedures, particularly in the realms of hernia repair, abdominal wall reconstructions, and plastic and reconstructive surgery. TELA Bio has placed emphasis on utilizing a direct sales force to market its products, predominantly within the United States, thereby ensuring a focused and specialized approach towards addressing the needs of its clientele.
TELA Bio has developed a comprehensive portfolio of products designed to meet the diverse needs in soft-tissue reconstruction: